SBIR/STTR Research Award

Targeted Antimicrobial Treatment of Acne Vulgaris by Engineered High Molecular Weight Contractile Nanotubes

Award identifier c3be8229c3b51c12f775eaf4bf359262fbdba4a7db254994d46fde41436d1e5bAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$224,962

Program and phase

SBIR · Phase I

Award year

2015

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Dermalytica Inc.
Proposal award date
2015-08-01
Contract end date
2016-10-31
UEI
MJDHVBPJ52Y7
Solicitation number
PA14-071
Topic code
NIAMS

Research abstract

DESCRIPTION provided by applicant Acne is a common dermatological condition particularly amongst teenagers with a large unmet medical need because of the rise of antibiotic resistant bacteria and the significant side effects of current treatments R type bacteriocins or andquot contractile nanotubesandquot CNTs are bactericidal proteins released by certain bacteria to confer a competitive advantage over related strains or other species The receptor binding protein in a CNT provides target specificity working in concert with the contractile scaffold to puncture the target cell depolarizing the membrane causing ion leakage and ultimately cell death Altering the receptor binding protein can retarget the novel hybrid CNT to the target bacteria of choice We will collaborate with AvidBiotics to utilize their CNT platform t engineer the receptor binding domains specific for P acnes the primary opportunistic pathogen causally linked to acne onto the contractile structural scaffolds of CNTs derived from Gram positive bacteria such as C difficile We therefore aim to create novel hybrid CNTs that would only attack P acnes Success in this proof of concept proposal will lead to further development of these antimicrobial proteins as effective acne therapeutics superior to current treatments PUBLIC HEALTH RELEVANCE Dermalytica Inc aims to develop novel and more effective treatments for acne a major dermatological condition particularly amongst teenagers that faces increasing incidence of resistance to broad spectrum antibiotics We will adapt and modify andquot natural anti microbialandquot proteins to specifically target the bacterial that causes acne Success in this proof of concept proposal will lead to further development of these agents as more effective therapeutics for acne

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

3 SBIR/STTR records share this UEI (2015–2020). Reported award amounts total $713,590. Reported amounts are not federal obligations.

Phases: Phase I

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.